Get started
Author

Zaineb Sharafali

Observed name: Sharafali Zaineb
ORCID: 0000-0002-4189-1132
Observed ORCID: 0000-0002-4189-1132
OpenAlex ID: A5018439866
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
2022 · William J Sandborn, Julian Panés, et al. · The Lancet. Gastroenterology & hepatology · 70
Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease
2021 · Bingbing Dai, Jason A. Hackney, et al. · Cell Reports Medicine · 54
PDF
OTU-003 Etrolizumab as induction therapy in moderate to severe crohn’s disease: results from bergamot cohort 1
2018 · Christian Selinger, William Sandborn, et al. · Gut · 25
Etrolizumab as Induction Therapy in Moderate to Severe Crohnʼs Disease: Results From BERGAMOT Cohort 1
2018 · Sandborn William, Panes Julian, et al. · The American Journal of Gastroenterology · 10
Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Carcinoid Syndrome: Results from a Phase 2 Multicentre Study
2026 · Aman Chauhan, Amr Mohamed, et al. · SSRN Electronic Journal
977: Minimal Clinically Important Difference (mcid) for the Crohn's Disease Patient-reported Outcomes Signs and Symptoms (cd-pro/ss) Tool
2022 · Rhian Jacob-Moffatt, Deanna Galloway, et al. · Gastroenterology
P035 Defining Responders for the Crohn’s Disease Patient-Reported Outcomes Signs and Symptoms (CD-PRO/SS) Tool Using Data From Patients Treated With Etrolizumab
2019 · Peter Higgins, Kendra DeBusk, et al. · The American Journal of Gastroenterology
Works count: 7
Citation count: 159
H-index: 4
I10-index: 4
Year
Topic
Type